High-throughput continuous evolution of compact Cas9 variants targeting single-nucleotide-pyrimidine PAMs

Tony P Huang1,2,3, Zachary J Heins4,5, Shannon M Miller1,2,3

  • 1Merkin Institute of Transformative Technologies in Healthcare, The Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Nature Biotechnology
|September 8, 2022
PubMed
Summary

Researchers engineered novel Cas9 variants to target previously inaccessible pyrimidine-rich PAM sequences in the human genome. These new variants offer improved editing efficiency and reduced off-target activity for gene editing applications.